Cargando…
The Prognostic Relevance of Poly (ADP-Ribose) Polymerase Expression in Ovarian Cancer Tissue of Wild Type and BRCA-Mutation Carrier Patients
(1) Background: The mechanism of platinum resistance in ovarian cancer is not fully clarified, but the properly functioning DNA repair mechanism can counteract the effect of conventional anticancer treatment. The objective of our study was to evaluate the expression of an important DNA repair enzyme...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7835745/ https://www.ncbi.nlm.nih.gov/pubmed/33478135 http://dx.doi.org/10.3390/diagnostics11010144 |
_version_ | 1783642594795847680 |
---|---|
author | Molnár, Szabolcs Vida, Beáta Beke, Lívia Méhes, Gábor Póka, Róbert |
author_facet | Molnár, Szabolcs Vida, Beáta Beke, Lívia Méhes, Gábor Póka, Róbert |
author_sort | Molnár, Szabolcs |
collection | PubMed |
description | (1) Background: The mechanism of platinum resistance in ovarian cancer is not fully clarified, but the properly functioning DNA repair mechanism can counteract the effect of conventional anticancer treatment. The objective of our study was to evaluate the expression of an important DNA repair enzyme, the Poly (ADP-Ribose) Polymerase (PARP) expression in epithelial ovarian cancer (EOC) tissues depending on BRCA status and to assess its relationship with platinum resistance. (2) Methods: Immunostaining to highlight PARP protein expression was performed using a rabbit polyclonal anti-PARP antibody. The intensity and distribution of immunostaining were assessed by light. Somatic BRCA1 or BRCA2 mutation carriers were identified with bidirectional sequencing of DNA from archived tumor tissue, if the test could not be performed due to technical reasons from tumor cells, the sequencing was done from peripheral blood cells to identify germline mutation carriers. The median progression-free survival (PFS) was generated for each semiquantitative group of PARP expression among chemotherapy-naive cases at the time of PARP immunohistochemistry. (3) Results: In the overall population, negative PARP immunohistochemistry predicted significant PFS (20.1 vs. 11.9 months, p = 0.001) and OS (49 vs. 114 months, p = 0.014) benefit. Genotype-stratified subgroup analysis in BRCA-negative cases confirmed the role of PARP positivity indicating an unfavorable prognosis in the entire population (relapsed 73.91% vs. 92%; OR: 4.06; p = 0.04). In the cases of the subgroup carrying the BRCA mutation, the presence of PARP expression was not associated with less favorable relapse rates, but with marginal significance for overall survival predicted a lower chance of survival (OS more than 32 months 72.73% vs. 35%; OR: 0.2; p = 0.05). (4) Conclusion: The BRCA wild type patients with strong expression of PARP enzymes before the first set of chemotherapy have a poor prognosis. |
format | Online Article Text |
id | pubmed-7835745 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-78357452021-01-27 The Prognostic Relevance of Poly (ADP-Ribose) Polymerase Expression in Ovarian Cancer Tissue of Wild Type and BRCA-Mutation Carrier Patients Molnár, Szabolcs Vida, Beáta Beke, Lívia Méhes, Gábor Póka, Róbert Diagnostics (Basel) Article (1) Background: The mechanism of platinum resistance in ovarian cancer is not fully clarified, but the properly functioning DNA repair mechanism can counteract the effect of conventional anticancer treatment. The objective of our study was to evaluate the expression of an important DNA repair enzyme, the Poly (ADP-Ribose) Polymerase (PARP) expression in epithelial ovarian cancer (EOC) tissues depending on BRCA status and to assess its relationship with platinum resistance. (2) Methods: Immunostaining to highlight PARP protein expression was performed using a rabbit polyclonal anti-PARP antibody. The intensity and distribution of immunostaining were assessed by light. Somatic BRCA1 or BRCA2 mutation carriers were identified with bidirectional sequencing of DNA from archived tumor tissue, if the test could not be performed due to technical reasons from tumor cells, the sequencing was done from peripheral blood cells to identify germline mutation carriers. The median progression-free survival (PFS) was generated for each semiquantitative group of PARP expression among chemotherapy-naive cases at the time of PARP immunohistochemistry. (3) Results: In the overall population, negative PARP immunohistochemistry predicted significant PFS (20.1 vs. 11.9 months, p = 0.001) and OS (49 vs. 114 months, p = 0.014) benefit. Genotype-stratified subgroup analysis in BRCA-negative cases confirmed the role of PARP positivity indicating an unfavorable prognosis in the entire population (relapsed 73.91% vs. 92%; OR: 4.06; p = 0.04). In the cases of the subgroup carrying the BRCA mutation, the presence of PARP expression was not associated with less favorable relapse rates, but with marginal significance for overall survival predicted a lower chance of survival (OS more than 32 months 72.73% vs. 35%; OR: 0.2; p = 0.05). (4) Conclusion: The BRCA wild type patients with strong expression of PARP enzymes before the first set of chemotherapy have a poor prognosis. MDPI 2021-01-19 /pmc/articles/PMC7835745/ /pubmed/33478135 http://dx.doi.org/10.3390/diagnostics11010144 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Molnár, Szabolcs Vida, Beáta Beke, Lívia Méhes, Gábor Póka, Róbert The Prognostic Relevance of Poly (ADP-Ribose) Polymerase Expression in Ovarian Cancer Tissue of Wild Type and BRCA-Mutation Carrier Patients |
title | The Prognostic Relevance of Poly (ADP-Ribose) Polymerase Expression in Ovarian Cancer Tissue of Wild Type and BRCA-Mutation Carrier Patients |
title_full | The Prognostic Relevance of Poly (ADP-Ribose) Polymerase Expression in Ovarian Cancer Tissue of Wild Type and BRCA-Mutation Carrier Patients |
title_fullStr | The Prognostic Relevance of Poly (ADP-Ribose) Polymerase Expression in Ovarian Cancer Tissue of Wild Type and BRCA-Mutation Carrier Patients |
title_full_unstemmed | The Prognostic Relevance of Poly (ADP-Ribose) Polymerase Expression in Ovarian Cancer Tissue of Wild Type and BRCA-Mutation Carrier Patients |
title_short | The Prognostic Relevance of Poly (ADP-Ribose) Polymerase Expression in Ovarian Cancer Tissue of Wild Type and BRCA-Mutation Carrier Patients |
title_sort | prognostic relevance of poly (adp-ribose) polymerase expression in ovarian cancer tissue of wild type and brca-mutation carrier patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7835745/ https://www.ncbi.nlm.nih.gov/pubmed/33478135 http://dx.doi.org/10.3390/diagnostics11010144 |
work_keys_str_mv | AT molnarszabolcs theprognosticrelevanceofpolyadpribosepolymeraseexpressioninovariancancertissueofwildtypeandbrcamutationcarrierpatients AT vidabeata theprognosticrelevanceofpolyadpribosepolymeraseexpressioninovariancancertissueofwildtypeandbrcamutationcarrierpatients AT bekelivia theprognosticrelevanceofpolyadpribosepolymeraseexpressioninovariancancertissueofwildtypeandbrcamutationcarrierpatients AT mehesgabor theprognosticrelevanceofpolyadpribosepolymeraseexpressioninovariancancertissueofwildtypeandbrcamutationcarrierpatients AT pokarobert theprognosticrelevanceofpolyadpribosepolymeraseexpressioninovariancancertissueofwildtypeandbrcamutationcarrierpatients AT molnarszabolcs prognosticrelevanceofpolyadpribosepolymeraseexpressioninovariancancertissueofwildtypeandbrcamutationcarrierpatients AT vidabeata prognosticrelevanceofpolyadpribosepolymeraseexpressioninovariancancertissueofwildtypeandbrcamutationcarrierpatients AT bekelivia prognosticrelevanceofpolyadpribosepolymeraseexpressioninovariancancertissueofwildtypeandbrcamutationcarrierpatients AT mehesgabor prognosticrelevanceofpolyadpribosepolymeraseexpressioninovariancancertissueofwildtypeandbrcamutationcarrierpatients AT pokarobert prognosticrelevanceofpolyadpribosepolymeraseexpressioninovariancancertissueofwildtypeandbrcamutationcarrierpatients |